| Neuroendocrine Tumors |
NCT00006238: Phenylbutyrate in Treating Children With Progressive or Recurrent Cancer of the Central Nervous System |
|
|
| Active, not recruiting | 2 | | US | sodium phenylbutyrate | Texas Children's Cancer Center, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | | | | |
2011-002632-99: Sunitinib in the treatment of metastatic Pheochromocytomas/Paragangliomas Sunitinib nel trattamento dei feocromocitomi/paragangliomi in fase avanzata non operabili |
|
|
| Ongoing | 2 | 46 | Europe | Capsule, SUTENT*30CPS 50MG | ISTITUTO NAZIONALE PER LA CURA TUMORI, Pfizer Italia Srl | Patients with unresectable and/or metastatic pheochromocytomas/paragangliomas Pazienti affetti da Feocromocitomi/Paragangliomi in stadio avanzato e/o non resecabile, Patients with unresectable and/or metastatic pheochromocytoma/paraganglioma Pazienti affetti da Feocromocitomi/Paragangliomi in stadio avanzato e/o non operabile, Diseases [C] - Cancer [C04] | | | | |
2011-006234-16: Treatment of neuroendocrine tumours with radiolabelled somatostatin analogues Trattamento dei tumori neuroendocrini con analoghi della somatostatina radiomarcati |
|
|
| Ongoing | 2 | 110 | Europe | 177Lu-DOTA, TYR(3)OCTREOTATE, 90Y-DOTA,TYR3-OCTREOTATE, 177Lu-DOTATATE, 90Y-DOTATATE, Radiopharmaceutical precursor | ISTITUTO NAZIONALE PER LA CURA TUMORI, Fondazione IRCCS Istituto Nazionale dei Tumori | Patients bearing neuroendocrine tumour expressing somatostatin receptors refractory to conventional therapies Pazienti portatori di neoplasia neuroendocrina esprimente recettori per la somatostatina refrattaria ai trattamenti convenzionali, Neuroendocrine tumour in progression after conventional therapy Tumore neuroendocrino in progressione dopo terapia convenzionale, Diseases [C] - Cancer [C04] | | | | |
2012-003092-19: Reinduction protocol for patients with high-risk neuroblastoma in first relapse Protocollo di reinduzione per pazienti affetti da Neuroblastoma ad alto rischio in prima recidiva |
|
|
| Ongoing | 2 | 24 | Europe | Concentrate for solution for injection, Concentrate for solution for infusion, Solution for injection, Powder and solvent for solution for injection, Powder and solvent for solution for infusion | A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA, AIEOP, Ospedale Pediatrico Bambino Gesù | Relapsed High Risk Neuroblastoma Patients Pazienti affetti da Neuroblastoma ad alto rischio in recidiva, Relapsed High Risk Neuroblastoma Patients Pazienti affetti da neuroblastoma ad alto rischio recidivati, Diseases [C] - Cancer [C04] | | | | |
2011-005562-38: Safety and Efficacy of peripheral blood stem cell transplantation using specifically purified stem cell preparations derived from patient family members in paediatric and adult patients Sicherheit und Wirksamkeit der Blutstammzelltransplantation mit spezifisch aufgereinigten Stammzellpräparaten von Famililienmitgliedern der Patienten als Spender bei Kindern und Erwachsenen |
|
|
| Ongoing | 2 | 60 | Europe | TCRabCD19PBSC, TCRabCD19PBSC_cryo, Suspension for injection | Miltenyi Biotec GmbH, Miltenyi Biotec GmbH | Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor. Hämatologische oder nicht-hämatologische maligne Erkrankungen oder nicht bösartige Erkrankungen, die einer allogenen Blutstammzelltransplantation eines haploidentischen Spenders bedürfen., Severe diseases requiring allogenic blood stem cell transplantation. Schwere Erkrankungen, die einer allogenen Blutstammzelltransplantation bedürfen., Diseases [C] - Cancer [C04] | | | | |
2013-002605-65: Radioreceptor therapy with labeled somatostatin analogues in tumors with high expression of somatostatin receptors. Terapia radiorecettoriale con analoghi marcati della somatostatina in tumori con elevata espressione dei recettori per la somatostatina. |
|
|
| Ongoing | 2 | 100 | Europe | Analogo Somatostatina marcato con 90Yttrium- DOTA (Tyr3)- octreotate 177 Lutetium DOTA (Tyr3), NA, Kit for radiopharmaceutical preparation | Azienda Ospedaliera di Reggio Emilia Arcispedale S.Maria Nuova/IRCCS, Azienda Ospedaliera di Reggio Emilia Arcispedale S.Maria Nuova/IRCCS | Patients with tumors expressing somatostatin receptors. Pazienti con tumori esprimenti recettori della somatostatina., Cancer patients with high expression of somatostatin receptors (neuroendocrine tumors, thyroid tumors, lung tumors, meningiomas, etc.) Pazienti con neoplasia ad elevata espressione di recettori della somatostatina (es. tumori neuroendocrini, tumori della tiroide, tumori polmonari, meningiomi, ecc), Diseases [C] - Cancer [C04] | | | | |
NCT00426738: Neoadjuvant Gemcitabine, Oxaliplatin, and Radiation Therapy for Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 60 | US | Gemcitabine, Gemzar, Oxaliplatin, Radiation Therapy | Sidney Kimmel Comprehensive Cancer Center, University of Michigan | Pancreatic Cancer | 03/14 | | | |
2014-002741-21: Safety and tolerability of an injectable diagnostic radiopharmaceutical (68Ga-DOTATOC) in patients with proven gastro-entero-pancreatic neuroendocrine tumors. |
|
|
| Ongoing | 2 | 20 | Europe | Kit for the preparation of 68Ga-DOTATOC for injection, Kit for radiopharmaceutical preparation | Advanced Accelerator Applications SA, Advanced Accelerator Applications SA | Patients with proven gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs), Patients suffering from a specific type of malignant tumours of the gastrointestinal tract named GEP-NETs., Diseases [C] - Cancer [C04] | | | | |
2014-003951-72: evaluation of the activity of Everolimus as maintenance therapy for metastatic neuroendocrine carcinoma with pulmonary or gastroenteropancreatic origin. Valutazione dell'attività di Everolimus come terapia di mantenimento per Il trattamento dei pazienti con carcinoma neuroendocrino di origine polmonare e gastroenteropancreatica |
|
|
| Ongoing | 2 | 30 | Europe | AFINITOR®, L01XE10, Capsule, AFINITOR® | Gruppo Oncologico Italiano Ricerca Cancro (GOIRC), GOIRC, NOVARTIS | The aim of this study is to evaluate the activity of a maintenance therapy with everolimus 10 mg daily in patients with stable disease, partial response or complete response after 6 cycles of induction chemotherapy with cisplatin or carboplatin plus etoposide administered according to clinical practice. L'obiettivo dello studi è quello di valutare l'attività di everolimus come terapia di mantenimento con everolimus 10 mg al giorno in pazienti con malattia stabile, in risposta parziale o completa dopo 6 cicli di chemioterapia con cisplatino ed etoposide somministrata in accordo con la pratica clinica, patients with neuroendocrine carcinoma with ki 67 less then 55% valutare l’attività di Everolimus in termini di PFS nella terapia di mantenimento di pazienti con carcinoma neuroendocrino con ki 67 inferiore al 55%., Diseases [C] - Cancer [C04] | | | | |
2013-000370-30: Diagnosis and follow up of neuroendocrine tumours with PET/CT Diagnostik och uppföljning av neuroendokrina tumörer med PET/CT |
|
|
| Ongoing | 2 | 60 | Europe | 68Ga-DotaToc, Solution for injection/infusion | Norrlands University Hospital, Norrlands University Hospital | Neuroendocrine tumors Neuroendokrina tumörer, Neuroendocrine tumors origin from endocrine cells in the intestinal, pancreatic and bronchi-pulmonary system. Hormonal symptoms is seen in approximately half of the patients., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | | | | |
2005-004354-27: STREPTOZOTOCINE + MITOTANE IN THE TREATMENT OF ADRENO-CORTICAL CANCER PATIENTS PROGRESSED AFTER CHEMOTHERAPY WITH CISPLATIN CONTAINING SCHEME |
|
|
| Ongoing | 2 | | Europe | NA, NA, | AZIENDA OSPEDALIERA S. LUIGI GONZAGA | Chemotherapy in patients with locally advanced or metastatic adrenocortical cancer | | | | |
2005-001709-24: Estudio en fase II, abierto, multicéntrico, prospectivo y aleatorizado, con DTIC o la combinación de Gemcitabina y DTIC en sarcomas de partes blandas avanzados del adulto |
|
|
| Ongoing | 2 | 110 | Europe | gemcitabina, M01/142, Gemzar, Gemzar | Grupo Español de Investigación en Sarcomas (GEIS) | Sarcomas de partes blandas | | | | |
2006-000897-65: Therapy of tumors SSTR2 expressing using somatostatine analogs labeled with 90Y and 177 Lu. |
|
|
| Ongoing | 2 | 35 | Europe | 90-Y-DOTATOC, 177 - LUTETIUM DOTATATE, | AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA | Diagnosis of tumor classified as expressing SSRT2, the main class of tumors to be included in the study are advanced and metastatic neuroendocrine tumors but also breast, lungs and thyroid cancers always expressing SSRT2. | | | | |
2005-005219-36: A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors |
|
|
| Ongoing | 2 | 70 | Europe | gemcitabine, oxaliplatin, LY188011, Gemzar 200 mg, Eloxatin 5 mg/ml, Gemzar 1g, Gemzar 200 mg, Eloxatin 5 mg/ml, Gemzar 1g | Eli Lilly and Company Limited | Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors | | | | |
2006-001614-33: Appraisal of the role of the 68Ga-DOTANOC in the diagnostic by Positron emission tomography (PET) in the study of human tumors of neuroendocrine derivation |
|
|
| Ongoing | 2 | 150 | Europe | Ga-DOTANOC PET, | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | tumors of neuroendocrine derivation | | | | |
2006-005301-63: Phase II Trial of Docetaxel in Patients With Metastatic or Inoperable Medullary Thyroid Cancer |
|
|
| Ongoing | 2 | 16 | Europe | Taxotere, Taxotere concentrate and solvent for solution for infusion, Taxotere concentrate and solvent for solution for infusion | University Hospital Vienna | Metastatic or inoperable medullary thyroid cancer | | | | |
2007-005517-20: Receptor radionuclide therapy with [177Lu-DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial. |
|
|
| Ongoing | 2 | 200 | Europe | 177lu DOTATATE, | ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI | cancer patients | | | | |
2008-000983-17: Diagnostic procedure with 68Ga-labelled somatostatin analogues in tumours presumably expressing SSTR2 and/or 5 receptors, to be evaluated for treatment with the same analogues labelled with 90Y o 177Lu |
|
|
| Ongoing | 2 | 300 | Europe | 68 Ga-DOTATOC, | AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA | Valutation of expression of receptors SSTR2 and/or 5 in neoplastic patients | | | | |
2008-007153-13: An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment |
|
|
| Ongoing | 2 | 50 | Europe | EVEROLIMUS, RAD001, | I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY | Patients with neuroendocrine tumours | | | | |
|
2008-007965-22: Evaluating diagnostic challenges in the management of neuroendocrine tumours with peptide receptor radionuclide therapy |
|
|
| Ongoing | 2 | 60 | Europe | 90Yttrium-DOTATOC, 68Ga-DOTATOC, | Nuclear Medicine UZ Gasthuisberg, Gastroenterology UZ Gasthuisberg, Hepatology UZ Gasthuisberg, General Medical Oncology UZ Gasthuisberg, Radiopharmacy, Radiotherapy UZ Gasthuisberg | Patients with a histological proven neuroendocrine tumour, without other curative options. | | | | |
2007-007974-45: A phase II study of the combination of gemcitabine with 131I-MIBG therapy for children with neuroblastoma without other treatment options. |
|
|
| Ongoing | 2 | 31 | Europe | gemcitabine, | AMC, KIKA | relapsed or progressive neuroblastoma in pediatric patients of 1 to 18 years | | | | |
2009-012644-16: PHASE 2 SINGLE- ARM STUDIES OF TEMOZOLOMIDE IN COMBINATION WITH TOPOTECANIN REFRACTORY AND RELAPSED NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS |
|
|
| Ongoing | 2 | 20 | Europe | TEMODAL, HYCAMTIN, TEMODAL, HYCAMTIN | POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS | | | | |
2005-003254-10: A Phase II Study to determine the efficacy and safety of conventional dose oral Treosulfan in patients with advanced pre-treated Ewing’s Sarcoma |
|
|
| Ongoing | 2 | 25 | Europe | Treosulfan, Treosulfan, Treosulfan | University College London | Advanced and pre-treated Ewing’s Sarcoma | | | | |
2010-018456-27: Efficacia diagnostica della metodica 18F-DOPA-PET/TC nello studio del Neuroblastoma: confronto con scintigrafia 123I-MIBG. |
|
|
| Ongoing | 2 | 10 | Europe | IASODOPA, IASODOPA | AZIENDA OSPEDALIERA OSPEDALI GALLIERA | Soggetti affetti da neuroblastoma | | | | |
2009-012260-14: An open, non-randomized phase-2 study of efficacy and safety of treatment with 177Lutetium-DOTA0-Tyr3-octreotate in patients with neuroendocrine tumors |
|
|
| Ongoing | 2 | 100 | Europe | 177-LuDOTA-Tyr3-Octreotate, 177-LuDOTA-Tyr3-Octreotate, 177-LuDOTA-Tyr3-Octreotate | Department of Endocrine Oncology | Patients with malignant neuroendocrine tumours, not amenable to surgical treatment or radiofrequency ablation. Renal, bone marrow and liver function must be sufficient. | | | | |
2010-022975-67: 68Ga-DOTANOC as a PET tool to diagnose nueroendocrine tumors |
|
|
| Ongoing | 2 | 50 | Europe | GA68-DOTANOC, | AZIENDA U.L.S.S. N.8 DI ASOLO | Study of tumor neuroendocrin origin | | | | |
2011-002891-18: Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study. Radioterapia recettoriale con 177Lu-DOTATATE in tumori con recettori positivi per la somatostatina, studio di fase II |
|
|
| Ongoing | 2 | 400 | Europe | LU 177 DOTATATE, NA, | ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI, IRST | cancer patients pazienti oncologici | | | | |
2012-000510-10: Trial investigating the activity of 177 Lutetium dotatate in children with cancer in their nervous system |
|
|
| Ongoing | 2 | 24 | Europe | Lutetium-177 DOTATATE, n/a, | University of Birmingham, Cancer Research UK | Neuroblastoma | | | | |
2012-004313-13: A prospective study of the use of 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors. En prospektiv studie av användandet av 68Ga-DOTA-TATE PET/CT hos patienter med neuroendokrina tumörer. |
|
|
| Ongoing | 2 | 450 | Europe | 68Ga-DOTA-TATE, | Skåne University Hospital, Dept of Oncology, Skåne University Hospital, Dept of Oncology | Patients with neuroendocrine tumors, who are going to be diagnosed/evaluated with 68Ga-DOTA-TATE PET/CT instead of standard Octreoscan Patienter med neuroendokrina tumörer, som skall diagnostiseras/utvärderas med den radioaktiva isotopen 68Ga-DOTA-TATE PET/CT istället för Octreoscan som idag är standard. | | | | |
2012-003939-27: Objective evaluation of the effects of pasireotide on gastrointestinal and colorectal transit times, rectal wall properties, and postprandial response in patients with carcinoid diarrhea Undersøgelse af pasireotids effekt på transittiden gennem tarmen, endetarmens egenskaber samt respons efter fødeindtag hos patienter med diare grundet en neuroendokrin tumor |
|
|
| Ongoing | 2 | 15 | Europe | Signifor 0.6 mg s.c., Signifor 0.6 mg s.c. | Klaus Krogh, Novartis, Aarhus University | Patients with neuroendocrine tumors and carcinoid diarrhea | | | | |
2004-002420-18: A prospective, non-randomised, non-controlled, open label, multicentre phase II study: PTK 787/ZK222584 in patients with advanced neuroendocrine tumours |
|
|
| Ongoing | 2 | 30 | Europe | PTKZK 787, PTKZK 787, | Prof. B. Wiedenmann, Klinik für Gastroenterologie, Charité, Campus Virchow, CHARITE Universitätsmedizin Berlin Campus Virchow-Klinikum | Neuroendocrine Tumour | | | | |
| Ongoing | 2 | 20 | Europe | thalidomide, Celecoxib, Fenofibrate, Etoposide, Cyclophosphamide, Avastin, DepoCyte, Avastin, DepoCyte | Masaryk University, Masaryk University | recurrent or progressive medulloblastoma recidivující/progredující meduloblastom | | | | |
2012-000266-38: Målrettet behandling af Neuro Endokrine Tumorer med 177Lu-DOTATATE kombineret med ekstern bestråling af levermetastasermhp. øget optagelse af det radioaktive lægemiddel i metastaserne |
|
|
| Ongoing | 2 | 50 | Europe | | Department of Nuclear Medicine, Odense University Hospital, Department of Nuclear Medicine, Odense University Hospital | Gastroenteropancreatic neuroendocrine tumours, GEP-NET\'s. | | | | |
2012-002513-19: PET imaging of neuroendocrine tumours PET-kamera undersökning av neuroendokrina tumörer |
|
|
| Ongoing | 2 | 600 | Europe | 68Ga-DOTATOC, | Karolinska University Hospital Solna, Karolinska University Hospital | Neuroendocrine tumour Neuroendocrin tumör | | | | |
2006-006615-80: A Pilot Study in Metastatic Advanced Thyroid Cancer Evaluating the Safety and Efficacy of Sorafenib |
|
|
| Ongoing | 2 | 33 | Europe | Nexavar, Nexavar, Nexavar | Royal Marsden Nhs Foundation Trust | Patients with localled advanced or metastatic thyroid cancer . histological sub-types will include differentiated and medullary thyroid cancer. | | | | |
2007-002365-13: Sorafenib as adjuvant to radioiodine therapy in non-medullary thyroid carcinoma |
|
|
| Ongoing | 2 | 30 | Europe | Nexavar, Nexavar | Bayer B.V. | non-medullary thyroid carcinoma | | | | |
2011-003226-27: A Phase II Study of Pazopanib in Metastatic Merkel Cell Carcinoma (called UKMCC-01) |
|
|
| Ongoing | 2 | 25 | Europe | Pazopanib, Votrient, Votrient | University of Birmingham, Cancer Research UK, GlaxoSmithKline | Metastatic Merkel Cell Carcinoma | | | | |
NCT02258243: Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome |
|
|
| Active, not recruiting | 2 | 3 | US | aminolevulinic acid hydrochloride, 5-ALA HCl, ALA HCl, aminolevulinic acid HCl, photodynamic therapy, Light Infusion Therapy™, PDT, therapy, photodynamic, laboratory biomarker analysis, questionnaire administration | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Basal Cell Carcinoma of the Skin, Nevoid Basal Cell Carcinoma Syndrome | 10/16 | 12/17 | | |
NCT02093624: A Phase II Trial of Rituximab In Myasthenia Gravis |
|
|
| Not yet recruiting | 2 | 50 | US | Rituximab, Placebo | Yale University | Myasthenia Gravis | 05/17 | 12/17 | | |
2016-003946-99: A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood Estudio multicéntrico, fase 2 de nivolumab en combinación con ipilimumab para pacientes con tumores pediátricos sólidos avanzados del adulto |
|
|
| Ongoing | 2 | 98 | Europe | Nivolumab, Concentrate for solution for infusion, Opdivo, Yervoy | Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI), Bristol Mayer | Pediatric solid tumors presenting in adulthood Tumores pediátricos sólidos avanzados del adulto, Pediatric solid tumors presenting in adulthood Tumores pediátricos sólidos avanzados del adulto, Diseases [C] - Cancer [C04] | | | | |
2017-000369-54: Treatment of patients with neuro-endocrine tumor liver metastases: liver directed therapy with intra-arterially administrated radionuclide lutetium-177-dotatate Gerichtere behandeling van levermetastasen bij patiënten met neuroendocriene tumoren: Intra-arteriële behandeling met Lutetium-177-dotatate. |
|
|
| Ongoing | 2 | 25 | Europe | Lutathera, Solution for infusion | University Medical Center Utrecht, University Medical Center Utrecht | Patients with neuro-endocrine tumors with liver metastases with an indication for treatment with lutetium-177-dotatate, Patients with neuro-endocrine tumors with liver metastases, Diseases [C] - Cancer [C04] | | | | |
2017-001207-68: A study to investigate the efficacy of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic neuroendocrine tumors of the pancreas Studie zur Untersuchung der Wirksamkeit von Ramucirumab in Kombination mit Dacarbazin bei Patienten mit neuroendokrinen, fortgeschrittenen Tumoren der Bauchspeicheldrüse, welche eventuell schon Absiedlungen (Metastasen) gebildet haben. |
|
|
| Ongoing | 2 | 45 | Europe | Concentrate for solution for infusion, Cyramza 10 mg/ml | Martin-Luther-Universität Halle-Wittenberg, Lilly Deutschland GmbH | Progressive well-differentiated metastatic pancreatic neuroendocrine tumors Progrediente, gut differenzierte metastasierte pankreatische neuroendokrine Tumore, Progressive well-differentiated metastatic neuroendocrine tumors of the pancreas Neuroendokriner Tumor der Bauchspeicheldrüse, welcher fortgeschritten ist und eventuell schon Absiedlungen (Metastasen) gebildet hat, Diseases [C] - Cancer [C04] | | | | |
NCT02771743: Response-based Treatment of High-risk Neuroblastoma |
|
|
| Recruiting | 2 | 54 | RoW | Cisplatin, Doxorubicin, Etoposide, Cyclophosphamide, Ifosfamide, Carboplatin, Tandem HDCT/auto-SCT, Radiotherapy, Interleukin-2, Isotretinoin, MIBG | Samsung Medical Center | Newly Diagnosed High Risk Neuroblastoma | 03/20 | 03/23 | | |
| Recruiting | 2 | 500 | Europe | Proton radiotherapy | Uppsala University, Sahlgrenska University Hospital, Sweden, Karolinska University Hospital, University Hospital, Umeå, Region Örebro County, University Hospital, Linkoeping | Central Nervous System Tumour, Arteriovenous Malformation | 07/20 | 07/30 | | |
NCT02755675 / 2015-005642-59: uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung |
|
|
| Recruiting | 2 | 120 | Europe | 68Ga-NOTA-AE105 PET/CT | Rigshospitalet, Denmark | Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma, Large Cell Neuroendocrine Carcinoma of the Lung | 04/23 | 10/23 | | |
OCCLURANDOM, NCT02230176: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
|
|
| Recruiting | 2 | 80 | Europe | Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Advanced Accelerator Applications | Pancreatic Neuroendocrine Carcinoma | 10/23 | 10/23 | | |
3-Hole, NCT02317224: The Safety and Efficacy of "" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor |
|
|
| Recruiting | 2 | 240 | RoW | "3-Hole" subxiphorid and subcostal approach, 3-Hole approach, Trans sternal approach, median sternotomy, VATS approach, Video-assisted thoracoscope | Tang-Du Hospital | Thymectomy, Myasthenia Gravis | 12/24 | 12/24 | | |
NCT01645683: Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma |
|
|
| Active, not recruiting | 2 | 36 | US | romidepsin, FK228, FR901228, Istodax | National Cancer Institute (NCI) | Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Malignant Hemangiopericytoma, Adult Malignant Mesenchymoma, Adult Neurofibrosarcoma, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma | 01/00 | | | |
NCT01766635: Interleukin 13 PE for Adults With Advanced Cancers |
|
|
| Recruiting | 1/2 | 33 | US | IL-13 PE | National Cancer Institute (NCI) | Adrenal Gland Neoplasms, Pancreatic Neoplasms, Liver Neoplasms | 08/15 | 08/15 | | |
NCT02330393: Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma |
|
|
| Not yet recruiting | 1/2 | 20 | US | Anti-PD-L1 Monoclonal Antibody MSB0010718C, MSB0010718C, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RT, Recombinant Interferon Beta, Betantrone, Betaseron, Feron, IFN-B, Rebif, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells, MCPyV TAg-specific polyclonal autologous CD8-positive T cells, Laboratory Biomarker Analysis | Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI) | Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma | 01/19 | | | |
NCT03633734: Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma |
|
|
| Recruiting | 1/2 | 49 | RoW | Sequential Treatment, Sequential Treatment With AG and Modified Folfirinox | Second Affiliated Hospital, School of Medicine, Zhejiang University | Pancreatic Adenocarcinoma Metastatic, Chemotherapy Effect | 08/23 | 12/24 | | |
